Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Beneficient filings on SEC EDGAR ↗
Beneficient reported financial results for its fiscal 2027 second quarter ended September 30, 2026, highlighting a significant reduction in year-to-date operating expenses to $26.6 million from $95.1 million in the prior year. The company is advancing strategic initiatives to eliminate $130 million in purported debt associated with its former CEO and plans to launch AltLens, an AI-driven portfolio analytics platform.
Term
Q2 2027
“Our second quarter results for FY 2027 demonstrated that we are continuing to make progress on multiple fronts: advancing financing initiatives, executing collateral management transactions, monetizing assets, pursuing new originations and follow-on business, and reducing operating expenses. Beneficient remains focused on putting legacy matters behind it as it moves to the next phase of its development, and we believe AltLens will be an important part of that strategy.”
Beneficient reported a net loss of $39.4 million for the quarter ended September 30, 2026, compared to a loss of $17.9 million in the prior year period. Total assets decreased to $227.3 million from $238.8 million at fiscal year-end, while the company's accumulated deficit grew to $2.12 billion.
Beneficient received a deficiency notice from Nasdaq on November 5, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has until May 4, 2027, to regain compliance by maintaining an MVLS of at least $35 million for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's Class A common stock (BENF) or warrants (BENFW).
Beneficient shareholders approved the issuance of Class A Common Stock to YA II PN, Ltd. (Yorkville) under an Amended and Restated Standby Equity Purchase Agreement (A&R SEPA). The approval satisfies Nasdaq Listing Rule 5635(d), allowing the company to issue shares representing more than 20% of its outstanding common stock upon the conversion of $4.0 million in promissory notes.
Beneficient filed a motion to intervene in Delaware Court of Chancery litigation against HCLP Nominees, L.L.C. to invalidate approximately $130 million in purported debt and recover $211 million previously paid. The company alleges the debt was fabricated by former CEO Brad Heppner as part of a fraudulent scheme for which he was convicted in May 2026.
Counterparty
HCLP Nominees, L.L.C.
“Mr. Heppner’s fraud should not continue to burden Beneficient and its stockholders. We are executing the strategy we outlined in September and are pursuing a comprehensive resolution that allows the Company to move forward. We will continue to take the steps necessary to achieve the objectives of that strategy, including additional litigation, while we seek an acceptable consensual resolution. This filing advances our efforts by placing our claims before the Court and seeking relief from the ongoing harm Heppner is causing. Our focus remains on strengthening Beneficient’s financial position and enabling the business to realize its potential.”
Beneficient's subsidiary entered into an amendment to a letter agreement with lender HH-BDH, LLC to extend the deadline for a $1.0 million cash payment. The payment, which covers remaining interest and fees under a 2023 credit agreement, was originally due in September 2026 and has been extended to March 31, 2027.
Beneficient announced a comprehensive strategy to eliminate approximately $130 million in fraudulent debt asserted by HCLP Nominees and $850 million in preferred equity interests held by former CEO Brad Heppner following his federal fraud conviction. The company is seeking a consensual resolution to convert Heppner's massive equity stake into just 162,132 Class A shares and terminate all remaining agreements to simplify its capital structure. If a resolution is not reached before Heppner's October 2026 sentencing, the company intends to pursue litigation to void the obligations and interests.
Beneficient announced the upcoming launch of AltLens, a technology-enabled alternative asset portfolio analytics and risk platform designed for family offices and small institutional investors. The platform, scheduled to go live in Q4 2026, provides institutional-level risk modeling, stress-testing, and allocation analysis based on historical private market data. This launch aims to capture growing demand for sophisticated oversight tools as global alternative assets under management are projected to reach $29 trillion by 2029.
Beneficient entered into subscription agreements with three of its executives and directors for the private placement of 33,019 shares of Class A common stock. The shares were sold at a price of $1.06 per share to CEO James G. Silk, Chief Fiduciary Officer Derek L. Fletcher, and Director Peter T. Cangany, Jr.
Counterparty
Peter T. Cangany, Jr., Derek L. Fletcher, and James G. Silk